Not sure if they have released details on the design before.
Design:
o Single-arm study with a 2-stage design: after treating 9 pts in the 1st stage, if > 2 respond (a
partial response or better), the trial will continue to the 2nd stage and a total of 24 pts will be
treated
o Each pt will be treated with up to 4 cycles of PAT-SM6 (6 mg/kg/dose) + carfilzomib (20-27
mg/m2
) + dexamethasone (40 mg)
o Each cycle will consist of 3 doses of PAT-SM6, 6 doses of carfilzomib and 4 doses of
dexamethasone administered over one month
Ann: Patrys Presents at AusBiotech Invest 2014, page-3
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $528 | 66.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 4671418 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 960403 | 8 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.7¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.7¢ | 0.7¢ | 0.7¢ | 156250 | ||
| Last updated 10.36am 14/06/2024 ? | |||||
| PAB (ASX) Chart |